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AMP-activated protein kinase (AMPK) is a sensor of cellular energy status. In pancreatic beta cells,
glucose induces the dephosphorylation of Thr172 within the catalytic subunit and the inactivation
of the AMPK complex. Here we demonstrate that glucose also activates protein kinase A (PKA), lead-
ing to the phosphorylation of AMPKa at Ser485 and Ser497. However, these modiﬁcations do not
impair the phosphorylation of Thr172 by upstream kinases, and phosphorylation of Thr172 does
not affect the phosphorylation of AMPKa by PKA either. Thus, although phosphorylation of
Thr172 and Ser485/Ser497 are inversely correlated in response to glucose, they follow an indepen-
dent regulation.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Mammalian AMP-activated protein kinase (AMPK) is a serine/
threonine protein kinase that acts as a sensor of the cellular energy
status. AMPK is a heterotrimer composed of the catalytic AMPKa
and two regulatory subunits, one involved in the binding of AMP,
ADP and ATP (AMPKc), and the other acting as a scaffold that
determines the subcellular localization of the complex (AMPKb)
[1]. Several isoforms of each subunit have been described (a1,
a2, b1, b2, c1, c2 and c3) that are expressed in a tissue-speciﬁc
manner. AMPK activity is regulated by two mechanisms: (i) allo-
steric activation by AMP, and (ii) phosphorylation of Thr172 in
the catalytic domain of AMPKa by the upstream kinases LKB1
and CaMKKb [1]. It has recently been proposed that upon binding
of AMP or ADP to the AMPKc subunit, the AMPK complex under-
goes a conformational change that makes it a poorer substrate
for dephosphorylation [2,3]. Therefore, an AMP/ADP-induced con-
formational switch and the ensuing phosphorylation of the cata-
lytic subunit on Thr172 are the key factors that determine the
activity of AMPK.chemical Societies. Published by E
PK, AMP-activated protein
n kinase AIn pancreatic beta cells AMPK activation impairs glucose-stimu-
lated insulin secretion [4,5]. This effect raises some concerns about
the use of general activators of AMPK in the treatment of different
pathologies [6]. To overcome the action of AMPK on glucose-stim-
ulated insulin secretion, glucose induces the rapid dephosphoryla-
tion and inactivation of the pancreatic AMPK complex [4,7]. In fact,
we have recently demonstrated that the PP1-R6 protein phospha-
tase holoenzyme, composed of protein Ser/Thr phosphatase PP1
and the R6 (PPP1R3D) regulatory subunit, participates in the glu-
cose-induced dephosphorylation and inactivation of AMPK [8]. In
this way, glucose inactivates AMPK and, at the same time, induces
insulin production and secretion in pancreatic beta cells.
Recently, an alternative mechanism for the downregulation of
AMPK activity has been described. In adipocytes, protein kinase A
(PKA) phosphorylates AMPKa1 on Ser173, Ser485 and Ser497,
and this impedes the phosphorylation of Thr172 by upstream acti-
vating kinases [9]. These results are consistent with a previous re-
port indicating that in the INS1 beta cell line, activation of the PKA
pathway in response to drugs that elevate cellular cAMP results in
an enhancement of the phosphorylation of AMPKa1 at Ser485
which leads to the reduction of the phosphorylation status of
Thr172 and the inhibition of AMPK activity [10]. However, there
are conﬂicting results on the negative role of PKA on the regulation
of AMPK activity: it was reported that in human umbilical veinlsevier B.V. All rights reserved.
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the PKA pathway, increased the phosphorylation of AMPK at both
Thr172 and Ser485 sites [11], and that in adipocytes, activation of
PKA by isoproterenol or forskolin also increased phosphorylation
of Thr172 and AMPK activity [12]. Another protein kinase has been
implicated in the regulation of AMPK activity. In heart prepara-
tions, protein kinase B (PKB) also phosphorylates AMPKa at
Ser485, and this prevents LKB1 phosphorylation at Thr172,
decreasing the activity of AMPK [13]. However, it was not clear
at that time whether PKB could phosphorylate AMPKa at alterna-
tive sites. A more direct analysis of the effect of the modiﬁcation
of the Ser485 site on AMPK activity was obtained when AMPKa1
Ser485Ala and Ser485Asp mutants were analyzed. It was reported
that none of these mutants affected the overall AMPK activity, so it
was proposed that phosphorylation of this residue did not partici-
pate directly in the regulation of AMPK activity [14].
To explore whether the glucose-dependent phosphorylation of
AMPK (either by PKA or PKB) plays a role in the glucose-dependent
inhibition of AMPK in beta cells, we checked the phosphorylation
status of AMPKa1 at Ser485 and Ser497 in response to glucose
and assessed whether there was any correlation between the phos-
phorylation of AMPK at these sites and the phosphorylation status
of Thr172, an indicator of AMPK activation. Here, we present evi-
dence indicating that, although glucose regulation of the phos-
phorylation status of AMPKa1 at Thr172 and Ser485/Ser497 by
upstream kinases and PKA/PKB, respectively, are inversely corre-
lated, the phosphorylation of these sites follows an independent
regulation.
2. Materials and methods
2.1. Cell culture
Mouse insulinoma pancreatic beta cells (MIN6) were kindly
provided by Dr. Jun-Ichi Miyazaki (Osaka University, Japan). Cells
(passage 20–30) were grown and handled as described in [8]. For-
skolin, glyburide and nifedipine were obtained from Sigma
(Madrid, Spain). Plasmids pcDNA-AMPKa1, pcDNA-AMPKa1S485A,
pcDNA-AMPKa1S485D, pcDNA-AMPKa1S497A and pcDNA-AMP-
Ka1S497D have been previously described [9]. Plasmid pcDNA-
AMPKa1S485A/S497A was obtained by subcloning a fragment
from plasmid pHIS-AMPKa1S485A/S497A-b1-c1 into pcDNA3.
2.2. Small interference RNA silencing
Cells were treated with a negative control siRNA (mock) or with
siRNA oligonucleotides for PP1a and PP1b (Ambion, Madrid, Spain)
as in [8].
2.3. Immunoblotting
Cell lysis and protein extracts were obtained and analyzed as in
[8]. Cell extracts (30 lg) were boiled in electrophoresis sample buf-
fer and analyzed by SDS/PAGE and immunoblotting using appro-
priate antibodies: anti-AMPKa, anti-phospho-AMPKa-Thr172,
anti-phospho-AMPKa-Ser485, anti-AMPKb1, anti-phospho-LKB1-
Ser428 and anti-phospho-ACC-Ser79, from Cell Signaling
Technology (Hertfordshire, UK); anti-PP1a (C-19) from Santa Cruz
Biotechnology (Santa Cruz, USA); anti-PP1b from Sigma (Madrid,
Spain); anti-phospho-CREB-Ser133 from Millipore (Temecula,
USA); and anti-phospho-AMPKa-Ser497 [9]. Secondary antibodies
were from Santa Cruz Biotechnology (Santa Cruz, USA). Immuno-
blots were analyzed with the ECL+ reagent (GE Healthcare,
Barcelona, Spain) and chemiluminiscence was detected using a
FUJIFILM LAS-3000 lite imager.3. Results
3.1. Glucose induces phosphorylation of AMPKa1 at residues Ser485
and Ser497 and also dephosphorylation of Thr172
Glucose is a negative regulator of the AMPK activity in different
mammalian cell models, including pancreatic beta-cells ([4,7]).
Since activation of cAMP-dependent protein kinase A (PKA) by
either lipolytic hormones in adipocytes [9] or cAMP elevating
drugs in INS1 beta cells [10] prevents the activating phosphoryla-
tion of AMPKa1 at Thr172, we decided to study whether PKA is
also implicated in the glucose-induced inhibition of AMPKa in pan-
creatic beta-cells. With this aim, we used mouse pancreatic MIN6
beta-cells, a model for glucose-responsive primary beta-cells
[15], which mainly expresses AMPK of the a1b1c1 type [7].
MIN6 cells were grown under conditions of high (25 mM) or low
(3 mM) glucose before the determination of the phosphorylation
status of endogenous AMPKa1 on Thr172 (as a sign of AMPK acti-
vation) and Ser485 and Ser497 (as indicators of PKA phosphoryla-
tion; we assume that phosphorylation of Ser173 also happens at
the same time, but as we do not have good antibodies to detect
endogenous levels of this phosphosite, we do not present results
on this modiﬁcation), using phospho-epitope speciﬁc antibodies.
As shown in Fig. 1 (lane a), in cells growing in low glucose
(3 mM) AMPKa1 was heavily phosphorylated on Thr172 but only
marginally on Ser497. However, if cells were exposed to a high glu-
cose concentration (25 mM) for 1 h, the phosphorylation of Thr172
was reduced, in agreement with previous reports ([7,8]), whereas
the phosphorylation of Ser485 and Ser497 was clearly increased
(Fig. 1, lane b). Thus, glucose induced both the dephosphorylation
of Thr172 and the phosphorylation of Ser485 and Ser497. Intrigu-
ingly, the phosphorylation of AMPKa1 at Thr172 and Ser485/
Ser497 follows an inverse correlation: if cells grown in low glucose
were shifted to high glucose for 1 h and then shifted back to low
glucose for an extra hour, the phosphorylation levels of Thr172
and Ser485/Ser497 were reversed again (Fig. 1, lane c). Likewise,
if cells were grown overnight in high glucose and then shifted to
low glucose conditions, the phosphorylation of Thr172 and
Ser485/Ser497 increased and decreased, respectively (Fig. 1, lanes
d and e). In agreement with published observations, the phosphor-
ylation status of Thr172 correlated with an increase in AMPK activ-
ity, assessed by the phosphorylation status of one its targets,
namely acetyl-CoA carboxylase (ACC) at Ser79 (Fig. 1).
3.2. Phosphorylation of AMPKa1 by PKA does not prevent
phosphorylation of Thr172 by upstream kinases
It is known that glucose activates PKA in pancreatic beta-cells
[16]. To delineate a putative role of PKA in the glucose-induced
inhibition of AMPKa phosphorylation at Thr172, cells growing in
high glucose were shifted to low glucose conditions in the presence
or absence of 10 lM forskolin, a potent activator of adenylate cy-
clase and PKA signaling. We conﬁrmed that forskolin activated
PKA signaling by measuring the phosphorylation status of the tran-
scription factor CREB (pSer133-CREB), a well-established nuclear
substrate of PKA (Fig. 2A, lanes d and e). It should be pointed out
that CREB is only transiently phosphorylated by PKA [17], which
also explains why this phosphorylation is not observed in cells
growing overnight in high glucose. Forskolin also promoted the
phosphorylation of LKB1 (pSer428-LKB1), in agreement with the
described PKA-dependent phosphorylation of LKB1 [18] (Fig. 2A,
lanes d and e), and the phosphorylation of AMPKa1 at residues
Ser485 and Ser497 (Fig. 2A, lanes d and e). However, we did not ob-
serve changes in the rate of phosphorylation of Thr172 induced by
a shift from high to low glucose conditions, in cells treated or not
Fig. 1. Coordinated regulation of phosphorylation status of residues Thr172, Ser485 and Ser497 of AMPKa1 by glucose. Mouse pancreatic MIN6 beta cells were grown
overnight in low glucose medium (3 mM). Then cells were shifted to high glucose medium (25 mM) for 1 h and, when indicated, shifted back to low glucose conditions for an
extra hour. Additionally, cells growing overnight in high glucose medium (25 mM) were either maintained in this medium or shifted to low glucose for 1 h. Cell extracts
(30 lg) were prepared and the presence of endogenous phosphorylated AMPKa1-T172, AMPKa1-S485 and AMPKa1-S497 detected with phosphospeciﬁc antibodies. Levels of
endogenous AMPKb1 subunit were detected with anti-AMPKb1 antibodies and used as loading control. Blots were also probed with anti-phosphoSer79-ACC to assess the
activity of the AMPK complex. On the right, the intensity of the bands related to the levels of AMPKb1 is plotted [values are means ± S.E.M. of three independent experiments
(⁄P < 0.05, ⁄⁄P < 0.01) analyzed by independent sample ‘‘t’’ test.
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AMPK by PKA did not affect the phosphorylation of Thr172 by up-
stream kinases.
We also analyzed whether the absence of an active PKA path-
way affects the phosphorylation of AMPKa at Thr172. For that pur-
pose we treated cells with speciﬁc siRNAs to deplete the
expression of the major PKA isoforms (PKAa and PKAb) (Supple-
mentary Fig. S1). Although this treatment efﬁciently diminished
the activity of PKA, as illustrated by the decreased phosphorylation
of pSer133-CREB, it did not affect the corresponding dephosphoryl-
ation of Thr172. As expected, the glucose-induced phosphorylation
of Ser497 was reduced, albeit only partially. Therefore, the absence
of an active PKA pathway does neither interfere with the glucose-
induced dephosphorylation of AMPKa1 at Thr172 nor with the
phosphorylation of this residue by upstream kinases under low
glucose conditions.
In order to clarify the role of the phosphorylation of residues
Ser485 and Ser497 on the regulation of the phosphorylation of
Thr172 by glucose, we transfected MIN6 cells with plasmids
expressing wild type AMPKa1, or mutants in which the phosphor-
ylation of these sites was prevented (S485A, S497A or the double
S485A/S497A), or the phosphomimetic S485D or S497D mutants.
As shown in Fig. 2B, and in agreement with previous reports
[14], regulation of the phosphorylation of Thr172 by glucose fol-
lowed a similar trend in any of the assayed mutated forms, without
any signiﬁcant difference in the levels of this phosphosite among
them. Therefore, the phosphorylation of residues Ser485 and
Ser497 does not affect the regulation of the phosphorylation of
Thr172 by glucose. Our results suggest that the regulation of
pThr172 by glucose only happened on the pool of AMPKa1 sub-
units forming part of the trimeric AMPK complex (similar levels
of pThr172 were present in cells overexpressing or not AMPKa1),but not on free AMPKa1 subunits, present in excess. These results
also indicate that the phosphorylation status of Ser485 or S497 in
free AMPKa1 subunits was constitutive. Moreover, the phos-
phorylation of these residues was affected by the presence of a
non-phosphorylatable residue in the other site. Perhaps the intro-
duction of a non-phosphorylatable residue in one of these sites
prevents the access of the other site to its corresponding kinase.
3.3. Phosphorylation of AMPKa1 at Thr172 does not interfere with the
phosphorylation of residues Ser485 and Ser497
We also analyzed whether phosphorylation of AMPKa1 at
Thr172 affects the phosphorylation of Ser485 and Ser497. We have
recently demonstrated that the glucose-induced dephosphoryla-
tion of AMPKa1 at Thr172 is prevented by depleting MIN6 cells
of the PPP1CA and PPP1CB transcripts, encoding the PP1a and
PP1b isoforms of protein phosphatase PP1, respectively [8]. Hence,
we studied the glucose-induced phosphorylation of Ser485 and
Ser497 before and after depletion of these two major PP1 isoforms.
As shown in Fig. 3A, depletion of PP1a and PP1b, as conﬁrmed by
immunoblotting, partially prevented the glucose-induced dephos-
phorylation of AMPKa1 at Thr172 (Fig. 3, compare lanes b and d),
in accordance with previous data [8]. However, this depletion did
not impair the glucose-induced phosphorylation of residues
Ser485 and Ser497, or the glucose induced phosphorylation of
LKB1 at Ser428 (a sign of PKA activation). These results suggested
that the phosphorylation status of Thr172 does not interfere with
the phosphorylation of Ser485 and Ser497.
As an independent approach to further explore this notion, we
treated cells with glyburide, an inhibitor of KATP-sensitive channels.
The closure of these channels leads to a depolarization of the
plasma membrane and the opening of L-type voltage-dependent
Fig. 2. Phosphorylation of AMPK by PKA does not prevent phosphorylation of Thr172 by upstream kinases. (A) MIN6 cells were grown overnight in high glucose medium
(25 mM) and then shifted directly to low glucose medium in the presence or absence of 10 lM forskolin in order to activate PKA. At the indicated times, cell extracts were
prepared as described in Fig. 1 and analyzed using the indicated phosphospeciﬁc antibodies and with anti-AMPKb1 as loading control. On the right, the intensity of the bands
related to the levels of AMPKb1 is plotted [values are means ± S.E.M. of three independent experiments (⁄⁄P < 0.01) analyzed by independent sample ‘‘t’’ test. (B) MIN6 cells
were transfected with plasmids pcDNA3 (empty), pcDNA-AMPKa1, pcDNA-AMPKa1S485A, pcDNA-AMPKa1S497A, pcDNA-AMPKa1S485A/S497A, pcDNA-AMPKa1S485D
and pcDNA-AMPKa1S497D. Transfected cells were grown overnight in high glucose medium (25 mM) and then shifted to low glucose medium (3 mM) for 1 h. Cell extracts
were prepared as in Fig. 1 and analyzed using phospho-AMPKa1 T172, -S485, -S497 and anti-AMPKa antibodies. Higher levels of total AMPKa were detected in cells
transfected with plasmids containing different AMPKa forms. A higher exposure of the blot corresponding to the anti-phospho-S497 antibody is shown to demonstrate that
the mutant overexpressed forms are not recognized by this antibody. Similar results were obtained with the anti-phopho-S485 antibody (not shown).
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Ca2+ levels activates a Ca2+-dependent adenylate cyclase isoform
(AC type 3) in pancreatic beta-cells, the production of cAMP and
the activation of PKA (see [19] for review). Therefore, treatment
of the cells with glyburide activates PKA independently of glucose
metabolism. As expected, in glyburide treated cells grown under
low glucose conditions, the phosphorylation status of Thr172 was
not affected (Fig. 3B). However, we observed a clear activation of
PKA, assessed by an increase in the levels of pSer133-CREB, and a
clear increase in the phosphorylation of Ser485 and Ser497 in AMP-
Ka1. These results show, on one hand, that the phosphorylation of
Ser485 and Ser497 by PKA is independent of the phosphorylation
status of Thr172 and, on the other hand, that the closure of the KATP-
sensitive channels and the entry of Ca+2 inside the cells without the
presence of glucose is not sufﬁcient to induce the dephosphoryla-
tion of Thr172.3.4. The blockage of the entry of Ca2+ into pancreatic beta-cell does not
affect the dephosphorylation of Thr172 induced by glucose
It has recently been reported that an intracellular Ca2+ rise is
needed to promote the glucose-induced dephosphorylation of
eIF2a by PP1 in beta cells [20]. In order to check whether Ca2+ en-
try is also necessary for the glucose-induced dephosphorylation of
AMPKa1 at Thr172, we treated cells with nifedipine, an inhibitor of
L-type Ca2+ channels, avoiding in this way the entry of Ca2+ via the
plasma membrane [16]. Cells growing in low glucose conditions
were pretreated or not with 50 lM nifedipine and then shifted to
high glucose conditions. As expected, nifedipine treatment blocked
Ca2+ entry and decreased the activity of PKA pathway, as indicated
by the lower levels of pSer133-CREB (Fig. 4). The glucose-induced
phosphorylation of AMPKa1 at Ser485 and Ser497 was also re-
duced by a decreased PKA activity. However, the glucose-induced
Fig. 3. Phosphorylation of AMPKa1 at Thr172 does not interfere with the phosphorylation of residues Ser485 and Ser497 by PKA. (A) MIN6 cells were transfected with a
combination of 50 nM each of siRNAs designed to reduce the expression of the PP1a and PP1b isoforms, or with an unrelated siRNA (100 nM, mock). Transfected cells were
grown overnight in low glucose medium (3 mM) and then maintained in fresh low glucose medium or shifted to high glucose medium (25 mM) for 1 h. Cell extracts were
prepared as described in Fig. 1 and analyzed using the indicated phosphospeciﬁc antibodies. Extracts were also analyzed with anti-PP1a and PP1b antibodies to conﬁrm
depletion of endogenous PP1 isoforms and with anti-AMPKb1 as loading control. (B) MIN6 cells grown overnight in low glucose medium were treated with 10 lM glyburide
(to inhibit KATP-sensitive channels, leading to the entry of Ca+2 inside the cell and the activation of the PKA pathway) or with solvent (DMSO). At the indicated times, cell
extracts were prepared as described in Fig. 1 and analyzed using the indicated phosphospeciﬁc antibodies. Extracts were also analyzed with anti-AMPKb1 as loading control.
On the right, the intensity of the bands related to the levels of AMPKb1 is plotted [values are means ± S.E.M. of three independent experiments (⁄⁄P < 0.01) analyzed by
independent sample ‘‘t’’ test.
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treated or untreated cells (Fig. 4). Therefore, the blockage of the en-
try of Ca+2 does not affect the glucose-induced dephosphorylation
of Thr172.
4. Discussion
A tight regulation of the AMP-activated protein kinase (AMPK)
complex is of paramount importance in view of its key functionsin cell metabolism. Cumulative evidence indicates that the activa-
tion of AMPK depends on the phosphorylation status of Thr172 of
the catalytic subunit. This phosphorylation results from the action
of upstream kinases (which promote activation) and the action of
speciﬁc phosphatases (which promote inactivation). Here, we re-
port that in MIN6 pancreatic beta cells, glucose triggers both the
dephosphorylation of Thr172 and the phosphorylation of residues
Ser485 and Ser497 in AMPKa1, leading to the inactivation of the
AMPK complex. Although we have observed that the phosphoryla-
Fig. 4. The glucose-induced entry of Ca2+ inside pancreatic beta-cell does not affect the dephosphorylation of Thr172 induced by glucose. MIN6 cells were grown overnight in
low glucose medium (3 mM) and then pretreated or not with 50 lM nifedipine (an inhibitor of L-type Ca2+ channels) for 30 min. Then cells were shifted to high glucose
medium containing or not 50 lM nifedipine for the indicated times. Cell extracts were prepared as described in Fig. 1 and analyzed using the indicated phosphospeciﬁc
antibodies. Extracts were also analyzed with anti-AMPKb1 as loading control. On the right, the intensity of the bands related to the levels of AMPKb1 is plotted [values are
means ± S.E.M. of three independent experiments (⁄P < 0.05, ⁄⁄P < 0.01) analyzed by independent sample ‘‘t’’ test.
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related, our results suggest that the regulation of the phosphoryla-
tion of these sites is independent of each other. In addition, our
results indicate that the phosphorylation of Ser485 and Ser497
do not affect the phosphorylation status of Thr172, and probably
the activity of AMPK. Apparently, these results are in conﬂict with
previous reports which indicated that in INS1 beta cells, activation
of the PKA pathway in response to drugs that elevate cellular cAMP
leads to the reduction of the phosphorylation status of Thr172 [10].Fig. 5. Proposed model of independent regulation of the phosphorylation status of Thr17
AMPKc subunit ﬁlled with AMP (black oval) or with ATP (white rectangle).Perhaps the different cell line used could explain the discrepancy
of the results. It has also been described that protein kinase B
(PKB) also phosphorylates AMPKa at Ser485, and this prevents
LKB1 phosphorylation at Thr172, decreasing the activity of AMPK
[13]. Perhaps the use of different cell types (heart muscle cells ver-
sus MIN6 cells) or the phosphorylation of AMPKa by PKB at alter-
native sites, could account for these paradoxal ﬁndings.
We also report that the regulation of the phosphorylation status
of Thr172 is not affected by the closure of the KATP-sensitive2, Ser485 and Ser497. See text for details. KD, kinase domain in AMPKa; AMP sites in
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the entry of Ca+2 inside the cells. Although it cannot be discarded
that other glucose triggered signals may affect the phosphorylation
of Thr172, we favor the hypothesis that glucose mainly regulates
the dephosphorylation of Thr172 by altering the levels of ATP
and by enhancing the action of a speciﬁc phosphatase involved
in the dephosphorylation of this residue (PP1-R6). Thus, we pro-
pose the following order of events in the (in)activation of AMPK
(Fig. 5): when the glucose concentration is low, AMPKa1 is active
and fully phosphorylated at Thr172. In these conditions AMP levels
are high, which keeps AMPKc in a conformational state that pre-
vents the dephosphorylation of Thr172 by the protein phosphatase
PP1-R6, which is bound to the AMPKb subunit [8]. When the glu-
cose concentration increases, AMP levels drop and AMPK converts
to a conformation that is accessible for dephosphorylation of
Thr172 by protein phosphatase PP1-R6. Independently, glucose
also triggers the production of cAMP, leading to the activation of
PKA and the phosphorylation of AMPKa1, at least on residues
Ser485 and Ser497. If glucose becomes scarce, the increase in
AMP/ADP levels would induce a change in the conformation of
the AMPK complex, which would become a poorer substrate for
phosphatases, and LKB1, the main AMPK upstream kinase in beta
cells, will gain access to phosphorylate Thr172 resulting in AMPK
activation. At the same time, Ser485/Ser497 residues will become
dephosphorylated by an hitherto unidentiﬁed phosphatase (PKA-
PPase). Since LKB1 appears to be constitutively active, our results
point to a crucial role of the PP1-R6 phosphatase holoenzyme in
the regulation of the activity of AMPK in MIN6 cells.
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